Literature DB >> 22524251

Complementary prediction of cardiovascular events by estimated apo- and lipoprotein concentrations in the working age population. The Health 2000 Study.

Niku Oksala1, Ilkka Seppälä, Jussi Hernesniemi, Leo-Pekka Lyytikäinen, Mika Kähönen, Kari-Matti Mäkelä, Antti Reunanen, Antti Jula, Mika Ala-Korpela, Terho Lehtimäki.   

Abstract

BACKGROUND: Apolipoprotein A-I (apoA-I) and B (apoB) and multiple lipoprotein cardiovascular risk factors can be computationally estimated with our extended Friedewald approach (EFW) from classical inputs. Their impact on cardiovascular events and mortality in the working age population is not known.
METHODS: The working age (≤ 65 years, n = 5956) prospective population-based cohort (follow-up of 7.8 ± 0.9 years; 46,572 patient years, 409 non-fatal incident cardiovascular events, and 55 cardiovascular and 266 all-cause deaths) had their total serum cholesterol (TC), triglycerides (TG), and HDL-C measured. Continuous net reclassification improvement (NRI) was calculated.
RESULTS: In Cox models adjusted with cardiovascular risk factors, EFW-HDL(2)-C (HR 0.78, 95% CI 0.67-0.91; NRI 16.5%), apoA-I (HR 0.78, 95% CI 0.69-0.89; NRI 15.2%), apoB/apoA-I (HR 1.23, 95% CI 1.08-1.40; NRI 20.6%), and VLDL-TG (HR 1.15, 95% CI 1.05-1.25; NRI 20.1%) were associated with incident non-fatal cardiovascular events and improved risk prediction compared with TC, LDL-C, or non-HDL-C. Cardiovascular deaths could be best predicted with EFW apoB (HR 1.81, 95% CI 1.18-2.77; NRI 77.3%).
CONCLUSIONS: EFW approach-derived HDL(2)-C, apoA-I, apoB/apoA-I, and VLDL-TG improve prediction of non-fatal cardiovascular events, and apoB of cardiovascular mortality, and can be utilized for risk estimation in a working age population without extra cost.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22524251     DOI: 10.3109/07853890.2012.679962

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  4 in total

1.  A dose-response meta-analysis to evaluate the relationship between high-density lipoprotein cholesterol and all-cause and cardiovascular disease mortality.

Authors:  L Liu; M Han; R Qie; Q Li; X Zhang; J Zhang; S Zhan; L Zhang; Z Xu; C Zhang; F Hong
Journal:  J Endocrinol Invest       Date:  2021-10-21       Impact factor: 4.256

2.  Extended Serum Lipid Profile Predicting Long-Term Survival in Patients Treated for Abdominal Aortic Aneurysms.

Authors:  Niina Khan; Leo-Pekka Lyytikäinen; Jahangir Khan; Ilkka Seppälä; Antti Lehtomäki; Tommi Kuorilehto; Velipekka Suominen; Terho Lehtimäki; Niku Oksala
Journal:  World J Surg       Date:  2018-04       Impact factor: 3.352

Review 3.  Serum Cholesterol Levels and Risk of Cardiovascular Death: A Systematic Review and a Dose-Response Meta-Analysis of Prospective Cohort Studies.

Authors:  Eujene Jung; So Yeon Kong; Young Sun Ro; Hyun Ho Ryu; Sang Do Shin
Journal:  Int J Environ Res Public Health       Date:  2022-07-06       Impact factor: 4.614

4.  Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial.

Authors:  Ruben N Eppinga; Minke H T Hartman; Dirk J van Veldhuisen; Chris P H Lexis; Margery A Connelly; Erik Lipsic; Iwan C C van der Horst; Pim van der Harst; Robin P F Dullaart
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.